PROC
Procaps Group S.A.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · LU
$1.01
+0.00%Year over year
Reported trailing growth
- Revenue
- -4.8%
- EBITDA
- +1560.4%
- EBIT
- +2579.0%
- EPS
- +425.0%
- Free cash flow
- +96.9%
- Operating cash flow
- +31.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.1%
- EBITDA
- +25.7%
- EBIT
- +13.0%
- Net income
- +142.2%
- EPS
- +140.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2023